This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 113 No. 4 April 2004, pp. 754-761

National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-Month Outcomes of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder

MTA Cooperative Group*

* The MTA is a cooperative treatment study performed by 6 independent research teams in collaboration with the National Institute of Mental Health and the Office of Special Education Programs of the US Department of Education, Washington, DC

Objective. In the Multimodal Treatment Study of ADHD (MTA), the effects of medication management (MedMgt) and behavior modification therapy (Beh) and their combination (Comb) and usual community comparison (CC) in the treatment of attention-deficit/hyperactivity disorder (ADHD) differed at the 14-month assessment as a result of superiority of the MTA MedMgt strategy (Comb or MedMgt) over Beh and CC and modest additional benefits of Comb over MedMgt alone. Here we evaluate the persistence of these beneficial effects 10 months beyond the 14 months of intensive intervention.

Methods. Of 579 children who entered the study, 540 (93%) participated in the first follow-up 10 months after the end of treatment. Mixed-effects regression models explored possible persisting effects of the MTA medication strategy, the incremental benefits of Comb over MedMgt alone, and the possible superiority of Beh over CC on 5 effectiveness and 4 service use domains.

Results. The MTA medication strategy showed persisting significant superiority over Beh and CC for ADHD and oppositional-defiant symptoms at 24 months, although not as great as at 14 months. Significant additional benefits of Comb over MedMgt and of Beh over CC were not found. The groups differed significantly in mean dose (methylphenidate equivalents 30.4, 37.5, 25.7, and 24.0 mg/day, respectively). Continuing medication use partly mediated the persisting superiority of Comb and MedMgt.

Conclusion. The benefits of intensive MedMgt for ADHD extend 10 months beyond the intensive treatment phase only in symptom domains and diminish over time.


Key Words: ADHD • attention deficit • hyperactivity • stimulant medication • behavior therapy

Abbreviations: MTA, Multimodal Treatment Study of ADHD • RCT, randomized clinical trial • ADHD, attention-deficit/hyperactivity disorder • MedMgt, medication management • Beh, behavior therapy • Comb, combined treatment • CC, community comparison • ITT, intention-to-treat • ODD, oppositional defiant disorder


Received for publication Mar 12, 2003; Accepted Jul 30, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Atten DisordHome page
A. Faber Taylor and F. E. Kuo
Children With Attention Deficits Concentrate Better After Walk in the Park
J Atten Disord, March 1, 2009; 12(5): 402 - 409.
[Abstract] [PDF]


Home page
J Pediatr PsycholHome page
D. Wallis, H. F. Russell, and M. Muenke
Review: Genetics of Attention Deficit/Hyperactivity Disorder
J. Pediatr. Psychol., November 1, 2008; 33(10): 1085 - 1099.
[Abstract] [Full Text] [PDF]


Home page
Remedial and Special EducationHome page
J. B. Ryan, R. Reid, and C. Ellis
Special Educators' Knowledge Regarding Psychotropic Interventions for Students With Emotional and Behavioral Disorders
Remedial and Special Education, September 1, 2008; 29(5): 269 - 279.
[Abstract] [PDF]


Home page
J Atten DisordHome page
J. Swanson, L. E. Arnold, H. Kraemer, L. Hechtman, B. Molina, S. Hinshaw, B. Vitiello, P. Jensen, K. Steinhoff, M. Lerner, et al.
Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA): Part I: Executive Summary
J Atten Disord, July 1, 2008; 12(1): 4 - 14.
[Abstract] [PDF]


Home page
FocusHome page
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Focus, July 1, 2008; 6(3): 401 - 426.
[Abstract] [Full Text] [PDF]


Home page
J Atten DisordHome page
J. Swanson, L. E. Arnold, H. Kraemer, L. Hechtman, B. Molina, S. Hinshaw, B. Vitiello, P. Jensen, K. Steinhoff, M. Lerner, et al.
Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA): Part II: Supporting Details
J Atten Disord, July 1, 2008; 12(1): 15 - 43.
[Abstract] [PDF]


Home page
J Child NeurolHome page
L. M. Furman
Attention-Deficit Hyperactivity Disorder (ADHD): Does New Research Support Old Concepts?
J Child Neurol, July 1, 2008; 23(7): 775 - 784.
[Abstract] [PDF]


Home page
CirculationHome page
V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Circulation, May 6, 2008; 117(18): 2407 - 2423.
[Full Text] [PDF]


Home page
EDUCATION AND PRACTICEHome page
V A Harpin
Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006
Arch. Dis. Child. Ed. Pract., April 1, 2008; 93(2): 58 - 65.
[Abstract] [Full Text] [PDF]


Home page
J Atten DisordHome page
G. DuPaul and T. J. Power
Improving School Outcomes for Students With ADHD: Using the Right Strategies in the Context of the Right Relationships
J Atten Disord, March 1, 2008; 11(5): 519 - 521.
[PDF]


Home page
J Atten DisordHome page
D. L. Clark, L. E. Arnold, L. Crowl, H. Bozzolo, M. Peruggia, Y. Ramadan, R. Bornstein, J. A. Hollway, S. Thompson, K. Malone, et al.
Vestibular Stimulation for ADHD: Randomized Controlled Trial of Comprehensive Motion Apparatus
J Atten Disord, March 1, 2008; 11(5): 599 - 611.
[Abstract] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
S. Timimi
Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues
Adv. Psychiatr. Treat., January 1, 2008; 14(1): 3 - 9.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
A. James
Pharmacotherapy and child psychiatry: is there a way forward?: INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY
Adv. Psychiatr. Treat., January 1, 2008; 14(1): 10 - 16.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
B. Kutzbach, C. G. Summers, A. M. Holleschau, R. A. King, and J. T. MacDonald
The Prevalence of Attention-Deficit/ Hyperactivity Disorder Among Persons With Albinism
J Child Neurol, December 1, 2007; 22(12): 1342 - 1347.
[Abstract] [PDF]


Home page
J Pediatr PsycholHome page
S. P. Hinshaw
Moderators and Mediators of Treatment Outcome for Youth With ADHD: Understanding for Whom and How Interventions Work
J. Pediatr. Psychol., July 1, 2007; 32(6): 664 - 675.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
U. Strehl, U. Leins, G. Goth, C. Klinger, T. Hinterberger, and N. Birbaumer
Self-regulation of Slow Cortical Potentials: A New Treatment for Children With Attention-Deficit/Hyperactivity Disorder
Pediatrics, November 1, 2006; 118(5): e1530 - e1540.
[Abstract] [Full Text] [PDF]


Home page
AAP Grand RoundsHome page
A. Schonwald
Pediatric Antipsychotic Prescription Rates Soar
AAP Grand Rounds, September 1, 2006; 16(3): 25 - 26.
[Full Text] [PDF]


Home page
J PsychopharmacolHome page
H. Ashton, P. Gallagher, and B. Moore
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
J Psychopharmacol, September 1, 2006; 20(5): 602 - 610.
[Abstract] [PDF]


Home page
Arch. Dis. Child.Home page
C R Steer
Managing attention deficit/hyperactivity disorder: unmet needs and future directions
Arch. Dis. Child., February 1, 2005; 90(suppl_1): i19 - i25.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. D. Rappley
Attention Deficit-Hyperactivity Disorder
N. Engl. J. Med., January 13, 2005; 352(2): 165 - 173.
[Full Text] [PDF]


Home page
FocusHome page
Abstracts FOR CHILD AND ADOLESCENT PSYCHIATRY
Focus, October 1, 2004; 2(4): 553 - 557.
[Full Text] [PDF]


Home page
PediatricsHome page
P. Panei, R. Arcieri, S. Vella, M. Bonati, N. Martini, and A. Zuddas
Italian Attention-Deficit/Hyperactivity Disorder Registry
Pediatrics, August 1, 2004; 114(2): 514 - 514.
[Full Text] [PDF]


Home page
PediatricsHome page
MTA Cooperative Group
National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: Changes in Effectiveness and Growth After the End of Treatment
Pediatrics, April 1, 2004; 113(4): 762 - 769.
[Abstract] [Full Text] [PDF]